MEETING REPORTER

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Opinion in Neurology

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1097/WCO.0000000000000521PMID 29481339
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Magnetic resonance imaging for the diagnosis of Parkinson’s disease

  2017cited by this paper
• Personalized medicine in Parkinson's disease: Time to be precise

  2017cited by this paper
• Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation

  2017cited by this paper
• Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial

  2017cited by this paper
• Meta‐analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease

  2017cited by this paper
• Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

  2017cited by this paper
• Key clinical milestones 15 years and onwards after DBS-STN surgery-A retrospective analysis of patients that underwent surgery between 1993 and 2001.

  2017cited by this paper
• Progression marker of Parkinson’s disease: a 4-year multi-site imaging study

  2017cited by this paper
• Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α‐synuclein Parkinson's disease rat model

  2017cited by this paper
• The Nonmotor Features of Parkinson's Disease.

  2017cited by this paper
• Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study

  2017cited by this paper
• Noradrenergic Deficits in Parkinson Disease Imaged with 11C-MeNER

  2017cited by this paper
• Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

  2017cited by this paper
• Long-term impact on quality of life of subthalamic nucleus stimulation in Parkinson’s disease

  2016cited by this paper
• Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With 123I‐FP‐CIT SPECT

  2016cited by this paper
• Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

  2016cited by this paper
• Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism

  2016cited by this paper
• Parkinson’s: a syndrome rather than a disease?

  2016cited by this paper
• In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.

  2016cited by this paper
• Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.

  2016cited by this paper
• Progression of Regional Microstructural Degeneration in Parkinson’s Disease: A Multicenter Diffusion Tensor Imaging Study

  2016cited by this paper
• Health-related quality of life in Parkinson’s: impact of ‘off’ time and stated treatment preferences

  2016cited by this paper
• Diagnostic Accuracy of Transcranial Sonography of the Substantia Nigra in Parkinson’s disease: A Systematic Review and Meta-analysis

  2016cited by this paper
• Free-water imaging in Parkinson's disease and atypical parkinsonism.

  2016cited by this paper
• Surviving 10 years with deep brain stimulation for Parkinson's disease – a follow‐up of 79 patients

  2016cited by this paper
• Correlation of 3D FLAIR and Dopamine Transporter Imaging in Patients With Parkinsonism.

  2016cited by this paper
• Clinical markers for identifying cholinergic deficits in Parkinson's disease

  2015cited by this paper
• Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease

  2015cited by this paper
• MRI signs of multiple system atrophy preceding the clinical diagnosis: the case for an imaging-supported probable MSA diagnostic category

  2015cited by this paper
• MDS research criteria for prodromal Parkinson's disease

  2015cited by this paper
• Cognitive impairment and resting‐state network connectivity in Parkinson's disease

  2015cited by this paper
• A multicontrast approach for comprehensive imaging of substantia nigra

  2015cited by this paper
• Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study.

  2015cited by this paper
• Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits

  2015cited by this paper
• The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases

  2014cited by this paper
• Molecular Imaging Insights into Neurodegeneration: Focus on α-Synuclein Radiotracers

  2014cited by this paper
• Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease.

  2014cited by this paper
• Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: an international multicenter study.

  2014cited by this paper
• Exercise: is it a neuroprotective and if so, how does it work?

  2014cited by this paper
• Early DEtection of wEaring off in Parkinson disease: the DEEP study.

  2014cited by this paper
• Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: from the advanced phase towards the late stage of the disease?

  2014cited by this paper
• Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations

  2014cited by this paper
• Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits.

  2013cited by this paper
• Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography

  2013cited by this paper
• The Value of GRE, ADC and Routine MRI in Distinguishing Parkinsonian Disorders

  2013cited by this paper
• Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia

  2013cited by this paper
• Visualization of nigrosome 1 and its loss in PD

  2013cited by this paper
• MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis

  2012cited by this paper
• [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism

  2012cited by this paper
• Late-stage Parkinson disease

  2012cited by this paper
• Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy

  2012cited by this paper
• MRI measurements of brainstem structures in patients with Richardson's syndrome, progressive supranuclear palsy–parkinsonism, and Parkinson's disease

  2011cited by this paper
• The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

  2011cited by this paper
• The Factor Structure of the UPDRS as an Index of Disease Progression in Parkinson's Disease

  2011cited by this paper
• Depression and anxiety related subtypes in Parkinson's disease

  2011cited by this paper
• Diagnostic Accuracy of Combined FP-CIT, IBZM, and MIBG Scintigraphy in the Differential Diagnosis of Degenerative Parkinsonism: A Multidimensional Statistical Approach

  2011cited by this paper
• Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease

  2011cited by this paper
• Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.

  2011cited by this paper
• Subthalamic Nucleus Stimulation Increases Brain Derived Neurotrophic Factor in the Nigrostriatal System and Primary Motor Cortex

  2011cited by this paper
• The Value of the Dopamine D2/3 Receptor Ligand 18F-Desmethoxyfallypride for the Differentiation of Idiopathic and Nonidiopathic Parkinsonian Syndromes

  2010cited by this paper
• Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.

  2010cited by this paper
• In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy.

  2010cited by this paper
• Does corticobasal degeneration exist? A clinicopathological re-evaluation.

  2010cited by this paper
• Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction.

  2010cited by this paper
• Papp–Lantos inclusions and the pathogenesis of multiple system atrophy: an update

  2010cited by this paper
• Significance of MRI in Diagnosis and Differential Diagnosis of Parkinson’s Disease

  2010cited by this paper
• Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis.

  2010cited by this paper
• High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease

  2009cited by this paper
• TRANSCRANIAL SONOGRAPHY IN MOVEMENT DISORDERS

  2009cited by this paper
• Transcranial duplex in the differential diagnosis of parkinsonian syndromes

  2009cited by this paper
• Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET

  2009cited by this paper
• The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study.

  2008cited by this paper
• Diagnostic Value of 123I-Ioflupane and 123I-Iodobenzamide SPECT Scans in 248 Patients with Parkinsonian Syndromes

  2008cited by this paper
• Second consensus statement on the diagnosis of multiple system atrophy

  2008cited by this paper
• The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years

  2008cited by this paper
• Tolcapone: An Efficacy and Safety Review (2007)

  2007cited by this paper
• Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.

  2007cited by this paper
• Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys.

  2007cited by this paper
• Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging

  2006cited by this paper
• Protection of nigral cell death by bilateral subthalamic nucleus stimulation.

  2006cited by this paper
• In vivo detection of iron and neuromelanin by transcranial sonography – a new approach for early detection of substantia nigra damage

  2006cited by this paper
• Subthalamic nucleus deep brain stimulation: Summary and meta‐analysis of outcomes

  2006cited by this paper
• The natural history of Parkinson’s disease

  2006cited by this paper
• Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease

  2005cited by this paper
• Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients

  2005cited by this paper
• Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

  2005cited by this paper
• Disease progression continues in patients with advanced Parkinson’s disease and effective subthalamic nucleus stimulation

  2005cited by this paper
• Hyperintense putaminal rim sign is not a hallmark of multiple system atrophy at 3T.

  2005cited by this paper
• FDG PET in the differential diagnosis of parkinsonian disorders

  2005cited by this paper
• Impact of the motor complications of Parkinson's disease on the quality of life

  2005cited by this paper
• A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.

  2005cited by this paper
• Levodopa and the progression of Parkinson's disease.

  2004cited by this paper
• Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.

  2004cited by this paper
• The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism

  2004cited by this paper
• Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

  2003cited by this paper
• Waiting for ON: A Major Problem in Patients With Parkinson Disease and ON/OFF Motor Fluctuations

  2003cited by this paper
• Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients.

  2002cited by this paper
• Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease

  2002cited by this paper
• Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings

  2001cited by this paper
• Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

  2000cited by this paper

• No citing papers are available for this paper.